CLEVELAND — Cleveland Clinic researchers are presenting encouraging findings from a Phase 1 clinical trial testing an experimental vaccine designed to prevent triple-negative breast cancer, the most aggressive and lethal form of the disease.

The study, presented Thursday at the San Antonio Breast Cancer Symposium , found the investigational vaccine produced an immune response in 74% of participants and was well tolerated with minimal side effects.

"Triple-negative breast cancer remains one of the most challenging forms of the disease to treat effectively," said Dr. G. Thomas Budd, principal investigator of the study at Cleveland Clinic's Cancer Institute. "The results from this trial are promising, as they suggest the investigational vaccine is not only safe and well tolerated but

See Full Page